MREO250117C500
- 4.10
- 0.000.00%
Mereo BioPharma Newsroom
Why Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now?
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Tuesday Trading
LifeSci Capital Initiates Coverage On Mereo BioPharma Group With Outperform Rating, Announces Price Target of $10
LifeSci Capital Initiates Mereo BioPharma(MREO.US) With Buy Rating, Announces Target Price $10
Mereo Biopharma's Potential in Rare Disease Therapy: Buy Rating and Strategic Partnership With Ultragenyx
Crude Oil Down 1%; Webuy Global Shares Spike Higher
Mereo BioPharma Shares Rise After Jefferies Begins Coverage at Buy
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Mereo BioPharma Group Price Target Announced at $7.00/Share by Jefferies
Mereo BioPharma Group Analyst Ratings
Jefferies Initiates Mereo BioPharma(MREO.US) With Buy Rating, Announces Target Price $7
Mereo BioPharma Files to Sell 26.64M Ordinary Shares for Holders
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)
Mereo BioPharma: Strong Cash Position Amid Clinical Progress
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
Mereo BioPharma | 8-K: Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Mereo BioPharma | 10-Q: Quarterly report
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7